|Bid||8.25 x 3200|
|Ask||8.39 x 3000|
|Day's range||9.88 - 10.84|
|52-week range||7.01 - 18.16|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.00|
Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...
Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had a good week last week, surging more than 13% in response to a positive second-quarter 2022 earnings report Thursday. Things got even worse today, when investors responded to a downgrade of 23andMe stock by a Citigroup analyst -- by selling off the stock by 10.1% (as of 11:30 a.m. EST). In my own note on the company last week, I pointed out that sales growth at 23andMe was a weak 7% in Q2, down steeply from Q1's 23% growth pace.
23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?